For example, some of our top candidates, such as phosphodiesterase inhibitors (Fig. 3A), are predicted to further increase cellular cAMP, which may actually exacerbate ADPKD-associated cellular phenotypes due to decreased intracellular mechanisms from defective PC1/PC2 calcium-sensing and transport. The gene discussed is PKD1; the disease is autosomal dominant polycystic kidney disease.